Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ranexa Could Be First Approval For First-Line Angina With MERLIN Trial

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

CV Therapeutics’ Ranexa could receive the first approval for first-line treatment of chronic angina if a new outcomes trial does not detect a trend towards death or arrhythmia, the company said.

You may also be interested in...

Ranexa Angina Reduction Enough For Restricted Indication, CVT Says

A mean weekly reduction of 0.4 angina attacks seen in the ERICA study with CV Therapeutics' Ranexa (ranolazine) is adequate for approval, the company said, despite being less than half the expected decrease

Ranexa ahead of schedule

CV Therapeutics expects to complete enrollment of its "approval-enabling study" of Ranexa by the end of the first quarter of 2005, the firm says Oct. 26. Prior to initiation in August 2004, the firm expected to complete enrollment of the Evaluation of Ranolazine In Chronic Angina study by the end of 2005. ERICA is being conducted under a special protocol assessment with FDA and is comparing ranolazine to the calcium channel blocker amlodipine (Pfizer's Norvasc) in 500 refractory chronic angina patients. Ranexa has been "approvable" at FDA since Oct. 30, 2003. Another study, MERLIN, is ongoing in support of a first-line indication (1Pharmaceutical Approvals Monthly Aug. 1, 2004, p. 10)...

NME "Approvables" Outnumber Approvals Six To Two In October

An "approvable" action was three times more likely than approval for the new molecular entities with user fee goals in October, according to an analysis by Pharmaceutical Approvals Monthly.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts